Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 28:9:F1000 Faculty Rev-54.
doi: 10.12688/f1000research.20928.1. eCollection 2020.

Precision medicine in inflammatory bowel disease: concept, progress and challenges

Simon P Borg-Bartolo  1 , Ray Kiran Boyapati  2   3 , Jack Satsangi  4 , Rahul Kalla  5
Affiliations
Review

Precision medicine in inflammatory bowel disease: concept, progress and challenges

Simon P Borg-Bartolo et al. F1000Res. .

Abstract

Crohn's disease and ulcerative colitis are increasingly prevalent, relapsing and remitting inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their aetiology remains unclear but current evidence shows an increasingly complex pathophysiology broadly centring on the genome, exposome, microbiome and immunome. Our increased understanding of disease pathogenesis is providing an ever-expanding arsenal of therapeutic options, but these can be expensive and patients can lose response or never respond to certain therapies. Therefore, there is now a growing need to personalise therapies on the basis of the underlying disease biology and a desire to shift our approach from "reactive" management driven by disease complications to "proactive" care with an aim to prevent disease sequelae. Precision medicine is the tailoring of medical treatment to the individual patient, encompassing a multitude of data-driven (and multi-omic) approaches to foster accurate clinical decision-making. In IBD, precision medicine would have significant benefits, enabling timely therapy that is both effective and appropriate for the individual. In this review, we summarise some of the key areas of progress towards precision medicine, including predicting disease susceptibility and its course, personalising therapies in IBD and monitoring response to therapy. We also highlight some of the challenges to be overcome in order to deliver this approach.

Keywords: Crohn's disease; biomarkers; genomics; inflammatory bowel disease; microbiome; precision medicine; prognosis; therapeutics; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Current progress towards precision medicine in inflammatory bowel disease.
This figure summarises some of the progress that has been made towards precision medicine in inflammatory bowel disease and the likely complex inter-relationship of multi-omic data.
Figure 2.
Figure 2.. The evolution of precision medicine in inflammatory bowel disease.
CRP, C-reactive protein; TPMT, thiopurine methyltransferase.
See this image and copyright information in PMC

References

    1. Torres J, Mehandru S, Colombel JF, et al. : Crohn's disease. Lancet. 2017;389(10080):1741–55. 10.1016/S0140-6736(16)31711-1 - DOI - PubMed
    1. Ungaro R, Mehandru S, Allen PB, et al. : Ulcerative colitis. Lancet. 2017;389(10080):1756–70. 10.1016/S0140-6736(16)32126-2 - DOI - PMC - PubMed
    1. Molodecky NA, Soon IS, Rabi DM, et al. : Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.e42; quiz e30. 10.1053/j.gastro.2011.10.001 - DOI - PubMed

    2. F1000 Recommendation

    1. Ng SC, Shi HY, Hamidi N, et al. : Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78. 10.1016/S0140-6736(17)32448-0 - DOI - PubMed
    1. Sýkora J, Pomahačová R, Kreslová M, et al. : Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018;24(25):2741–63. 10.3748/wjg.v24.i25.2741 - DOI - PMC - PubMed

Publication types

LinkOut - more resources